AU2024269116A1 — Novel targeting compound and use thereof, and nucleic acid conjugate and use thereof
Assigned to Sunshine Lake Pharma Co Ltd · Expires 2025-11-20 · 0y expired
What this patent protects
Provided are a targeting compound and the use thereof, and a nucleic acid conjugate and the use thereof. The present invention further relates to a conjugate group, which is used for the delivery of a small nucleic acid drug, and can be conjugated to a nucleotide to form a nuclei…
USPTO Abstract
Provided are a targeting compound and the use thereof, and a nucleic acid conjugate and the use thereof. The present invention further relates to a conjugate group, which is used for the delivery of a small nucleic acid drug, and can be conjugated to a nucleotide to form a nucleic acid conjugate. The nucleotide conjugate is used for the regulation of gene expression in hepatocytes to prevent and/or treat related diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.